Public Health, Nutrition & Epidemics21 Concepts & Facts

WHO Pathogen Access & Benefit-Sharing (PABS) System GK Facts & Guide

Reviewed by the Master10 Editorial Board for accuracy, clarity and competitive-exam relevance.Editorial Policy

The Pathogen Access and Benefit-Sharing (PABS) System is a specialized multilateral mechanism established under Article 12 of the World Health Organization Pandemic Agreement. Negotiated by the Intergovernmental Negotiating Body under Article 19 of the WHO Constitution, the system addresses acute structural inequities exposed during the COVID-19 pandemic. During international public health emergencies, scientists in developing countries routinely isolate novel disease strains and upload pathogen genetic sequence data to public databases. Historically, pharmaceutical corporations in developed nations utilized these shared genetic blueprints to manufacture lucrative vaccines, diagnostics, and therapeutic drugs, leaving the originating developing nations with little or no access during acute supply shortages. The PABS System establishes a legally binding quid pro quo: rapid pathogen sample and sequence sharing is coupled directly with fair, equitable access to resulting medical countermeasures.

Operationally, the PABS System governs biological materials and Genetic Sequence Data derived from Pathogens with Pandemic Potential, defined as biological agents capable of causing widespread human epidemics. Member states commit to depositing biological samples and digital genomic sequences into recognized WHO-coordinated laboratory networks and open-access databases promptly upon identification. In exchange, pharmaceutical and biotechnology manufacturers that utilize PABS materials must sign standardized legally binding PABS contracts with the World Health Organization. Under the agreed allocation formula, participating manufacturers must reserve twenty percent of their real-time production of pandemic health products for WHO distribution. Half of this reserved allocation—ten percent of total production—must be provided free of charge as an unconditional donation to low-income developing countries, while the remaining ten percent is sold to WHO at affordable non-profit prices for vulnerable populations.

The PABS framework builds on historical precedents while interacting with existing international environmental law. It expands upon the operational principles of the 2011 Pandemic Influenza Preparedness Framework, broadening access and benefit-sharing rules from influenza strains to all emerging pandemic threats. In legal terms, PABS functions as a specialized international access and benefit-sharing instrument recognized under Article 4 of the Nagoya Protocol to the Convention on Biological Diversity. Beyond physical allocations of vaccines and antiviral medications, the system mandates annual financial contributions from commercial entities and promotes voluntary technology transfer via mechanisms like the Medicines Patent Pool. A unified coalition of Global South nations, including India, South Africa, and the Africa Group, led negotiations to ensure that pathogen sharing cannot remain separated from equitable benefit distribution, establishing international health solidarity as a binding obligation rather than voluntary charity.

Key Concepts & Self-Assessment21 Key Facts

Review key WHO Pathogen Access and Benefit-Sharing (PABS) System: Pandemic Agreement Article 12 & Equity exam facts and rate your mastery to track revision.

Progress: 0/21 Rated 0 Mastered 0 Review Later

The Pathogen Access and Benefit-Sharing (PABS) System is codified under Article 12 of the WHO Pandemic Agreement.

The Pandemic Agreement is negotiated through the Intergovernmental Negotiating Body (INB) under Article 19 of the WHO Constitution.

The PABS System was formulated to overcome severe vaccine apartheid and diagnostic disparities witnessed during the COVID-19 pandemic.

The system covers biological materials and digital Genetic Sequence Data (GSD) of Pathogens with Pandemic Potential (PEMP).

Pathogens with pandemic potential exclude seasonal influenza viruses, which remain regulated under the 2011 PIP Framework.

Member states commit to uploading pathogen genetic sequences and shipping biological samples to WHO-designated laboratories rapidly.

Any manufacturer utilizing PABS materials or sequence data must enter into a formal, legally binding PABS contract with the WHO.

Participating commercial manufacturers must reserve at least 20 percent of their real-time production of pandemic countermeasures for the WHO.

Under the 20 percent quota, 10 percent of real-time production is donated free of charge to WHO for distribution to low-income countries.

#10

The remaining 10 percent of the quota is provided to WHO at affordable, transparent non-profit prices for developing nations.

#11

Pandemic countermeasures covered under PABS include preventive vaccines, therapeutic drugs, and diagnostic laboratory tests.

#12

Commercial users of the PABS System are required to pay annual monetary contributions into a dedicated WHO pandemic emergency fund.

#13

The PABS System promotes voluntary non-exclusive technology licensing to regional manufacturing hubs in low- and middle-income nations.

#14

The system operates as a specialized international access and benefit-sharing instrument under Article 4(4) of the Nagoya Protocol.

#15

Under the Convention on Biological Diversity (CBD), sovereign nations hold legal authority over biological resources found within their territories.

#16

The 2011 Pandemic Influenza Preparedness (PIP) Framework served as the foundational operational blueprint for the broader PABS structure.

#17

The Africa Group, India, Indonesia, and other developing nations championed the principle that pathogen access cannot be separated from benefit sharing.

#18

High-income nations initially resisted binding percentage quotas, preferring voluntary donations and commercial contract flexibility.

#19

PABS incorporates provisions for real-time monitoring and transparent supply tracking to avoid stockpiling and export restrictions during health crises.

#20

Genetic sequence data platforms participating in PABS must balance open scientific research access with commercial accountability tracking.

#21

The World Health Assembly oversees implementation, ensuring that global public health preparedness protects developing and developed nations equally.

Subject Specialist Commentary

Analytical perspective & practical exam advice from the Master10 academic board

Educator's Insight

The WHO PABS System is an international agreement designed to stop vaccine inequality during future pandemics. In the past, poorer nations shared virus samples freely, but pharmaceutical companies used that data to make vaccines that only wealthy nations could buy. PABS changes this by legally requiring drugmakers who use shared pathogen data to give twenty percent of their vaccines to the WHO for poorer countries.

For public health and international treaty questions, remember the core sharing ratio with the mnemonic 'Ten-Ten Twenty': Ten percent donated free, Ten percent at non-profit cost, totaling Twenty percent guaranteed real-time production. A classic prelims trap assumes PABS replaces the PIP Framework; remember that seasonal influenza remains under the 2011 PIP Framework, while PABS covers other pandemic pathogens. Also, note that PABS connects legally to the Nagoya Protocol on access and benefit-sharing.

WHO Pathogen Access & Benefit-Sharing (PABS) System GK Facts & Guide

Key Concepts & Self-Assessment21 Key Facts

Subject Specialist Commentary

Related Knowledge Topics to Discover

Looking for more GK practice?